Published in Heart Fail Clin on August 09, 2012
Animal models of heart failure with preserved ejection fraction. Neth Heart J (2016) 1.19
Obesity and insulin resistance induce early development of diastolic dysfunction in young female mice fed a Western diet. Endocrinology (2013) 1.19
Mitochondrial and cellular mechanisms for managing lipid excess. Front Physiol (2014) 1.00
Prokineticin receptor-1 is a new regulator of endothelial insulin uptake and capillary formation to control insulin sensitivity and cardiovascular and kidney functions. J Am Heart Assoc (2013) 0.88
Metabolic dysfunction in diabetic cardiomyopathy. Heart Fail Rev (2014) 0.88
Mineralocorticoid receptor blockade prevents Western diet-induced diastolic dysfunction in female mice. Am J Physiol Heart Circ Physiol (2015) 0.88
Diabetes and the heart: is there objective evidence of a human diabetic cardiomyopathy? Diabetes (2013) 0.86
Increasing Pyruvate Dehydrogenase Flux as a Treatment for Diabetic Cardiomyopathy: A Combined 13C Hyperpolarized Magnetic Resonance and Echocardiography Study. Diabetes (2015) 0.84
Restoring redox balance enhances contractility in heart trabeculae from type 2 diabetic rats exposed to high glucose. Am J Physiol Heart Circ Physiol (2014) 0.83
Subclinical Alterations of Cardiac Mechanics Present Early in the Course of Pediatric Type 1 Diabetes Mellitus: A Prospective Blinded Speckle Tracking Stress Echocardiography Study. J Diabetes Res (2015) 0.83
Mechanisms of diastolic dysfunction in heart failure with a preserved ejection fraction: If it's not one thing it's another. Circ Heart Fail (2013) 0.81
Updating experimental models of diabetic cardiomyopathy. J Diabetes Res (2015) 0.80
Glucagon‑like peptide‑1 protects cardiomyocytes from advanced oxidation protein product‑induced apoptosis via the PI3K/Akt/Bad signaling pathway. Mol Med Rep (2015) 0.79
Retinol-Binding Protein 4 Induces Cardiomyocyte Hypertrophy by Activating TLR4/MyD88 Pathway. Endocrinology (2016) 0.78
CXCR4 Antagonism Attenuates the Development of Diabetic Cardiac Fibrosis. PLoS One (2015) 0.78
Exendin-4 attenuates adverse cardiac remodelling in streptozocin-induced diabetes via specific actions on infiltrating macrophages. Basic Res Cardiol (2015) 0.78
The influence of real-time blood glucose levels on left ventricular myocardial strain and strain rate in pediatric patients with type 1 diabetes mellitus - a speckle tracking echocardiography study. BMC Cardiovasc Disord (2015) 0.78
The mitochondria in diabetic heart failure: from pathogenesis to therapeutic promise. Antioxid Redox Signal (2015) 0.78
Protective mechanisms of mitochondria and heart function in diabetes. Antioxid Redox Signal (2015) 0.78
An Overview of Murine High Fat Diet as a Model for Type 2 Diabetes Mellitus. J Diabetes Res (2016) 0.77
Atorvastatin alleviates experimental diabetic cardiomyopathy by suppressing apoptosis and oxidative stress. J Mol Histol (2015) 0.77
Exercise ameliorates high fat diet induced cardiac dysfunction by increasing interleukin 10. Front Physiol (2015) 0.77
Role of cardiac MRI in diabetes. Curr Cardiol Rep (2014) 0.77
Bedside-to-Bench Translational Research for Chronic Heart Failure: Creating an Agenda for Clients Who Do Not Meet Trial Enrollment Criteria. Clin Med Insights Cardiol (2015) 0.77
Triptolide improves systolic function and myocardial energy metabolism of diabetic cardiomyopathy in streptozotocin-induced diabetic rats. BMC Cardiovasc Disord (2015) 0.76
B cells interactions in lipid immune responses: implications in atherosclerotic disease. Lipids Health Dis (2017) 0.76
Metformin attenuates myocardial ischemia-reperfusion injury via up-regulation of antioxidant enzymes. PLoS One (2017) 0.75
My Sweetheart Is Broken: Role of Glucose in Diabetic Cardiomyopathy. Diabetes Metab J (2017) 0.75
Youth with type 1 diabetes have worse strain and less pronounced sex differences in early echocardiographic markers of diabetic cardiomyopathy compared to their normoglycemic peers: A RESistance to InSulin in Type 1 ANd Type 2 diabetes (RESISTANT) Study. J Diabetes Complications (2016) 0.75
Sitagliptin attenuates cardiomyopathy by modulating the JAK/STAT signaling pathway in experimental diabetic rats. Drug Des Devel Ther (2016) 0.75
Evidence for distinct effects of exercise in different cardiac hypertrophic disorders. Life Sci (2015) 0.75
Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes. Cardiovasc Diabetol (2017) 0.75
Heart, lipids and hormones. Endocr Connect (2017) 0.75
Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med (2008) 47.90
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med (2008) 38.76
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ (2000) 35.06
Inflammation and metabolic disorders. Nature (2006) 33.33
Diabetes and cardiovascular disease. The Framingham study. JAMA (1979) 11.95
PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell (2000) 10.25
New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol (1972) 4.86
Advanced glycation end-products: a review. Diabetologia (2001) 4.59
Myocardial fatty acid metabolism in health and disease. Physiol Rev (2010) 4.49
A novel mouse model of lipotoxic cardiomyopathy. J Clin Invest (2001) 4.35
Lipotoxicity: when tissues overeat. Curr Opin Lipidol (2003) 4.20
Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ (2007) 3.95
Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study. Circulation (2007) 3.88
Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J (2004) 3.70
Impact of diabetes on cardiac structure and function: the strong heart study. Circulation (2000) 3.56
Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation (2004) 3.51
Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J Am Coll Cardiol (2008) 3.43
Disruption of leptin signaling contributes to cardiac hypertrophy independently of body weight in mice. Circulation (2003) 3.30
Reduced mitochondrial oxidative capacity and increased mitochondrial uncoupling impair myocardial energetics in obesity. Circulation (2005) 3.22
Mitochondrial energetics in the heart in obesity-related diabetes: direct evidence for increased uncoupled respiration and activation of uncoupling proteins. Diabetes (2007) 3.20
Myocardial cell death in human diabetes. Circ Res (2000) 3.12
Mitochondrial energy metabolism in heart failure: a question of balance. J Clin Invest (2005) 2.98
Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat. Circ Heart Fail (2008) 2.93
Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation (2004) 2.73
A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc Natl Acad Sci U S A (2003) 2.68
Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes (2005) 2.64
Evidence for cardiomyopathy in familial diabetes mellitus. J Clin Invest (1977) 2.53
Transgenic expression of fatty acid transport protein 1 in the heart causes lipotoxic cardiomyopathy. Circ Res (2004) 2.50
Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options. Am J Med (2008) 2.42
Lipoprotein lipase (LpL) on the surface of cardiomyocytes increases lipid uptake and produces a cardiomyopathy. J Clin Invest (2003) 2.39
Recipes for creating animal models of diabetic cardiovascular disease. Circ Res (2007) 2.34
A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. J Am Coll Cardiol (2012) 2.23
Substrate-specific derangements in mitochondrial metabolism and redox balance in the atrium of the type 2 diabetic human heart. J Am Coll Cardiol (2009) 2.20
PPAR signaling in the control of cardiac energy metabolism. Trends Cardiovasc Med (2000) 2.19
Protection of cardiac mitochondria by overexpression of MnSOD reduces diabetic cardiomyopathy. Diabetes (2006) 2.12
Diabetes in heart failure: prevalence and impact on outcome in the population. Am J Med (2006) 2.09
Role of changes in cardiac metabolism in development of diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol (2006) 1.97
Insulin-resistant heart exhibits a mitochondrial biogenic response driven by the peroxisome proliferator-activated receptor-alpha/PGC-1alpha gene regulatory pathway. Circulation (2007) 1.86
Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation (2005) 1.83
Metformin use and mortality in ambulatory patients with diabetes and heart failure. Circ Heart Fail (2010) 1.82
Catalase protects cardiomyocyte function in models of type 1 and type 2 diabetes. Diabetes (2004) 1.77
Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications. Ann N Y Acad Sci (2011) 1.60
Age-dependent changes in metabolism, contractile function, and ischemic sensitivity in hearts from db/db mice. Diabetes (2003) 1.56
Rodent models of diabetic cardiomyopathy. Dis Model Mech (2009) 1.56
Adaptive increase in pyruvate dehydrogenase kinase 4 during starvation is mediated by peroxisome proliferator-activated receptor alpha. Biochem Biophys Res Commun (2001) 1.50
Mechanisms of [Ca2+]i transient decrease in cardiomyopathy of db/db type 2 diabetic mice. Diabetes (2006) 1.49
Fibrosis in diabetes complications: pathogenic mechanisms and circulating and urinary markers. Vasc Health Risk Manag (2008) 1.49
Mechanisms for increased myocardial fatty acid utilization following short-term high-fat feeding. Cardiovasc Res (2009) 1.46
Relation of severe coronary artery narrowing to insulin or thiazolidinedione use in patients with type 2 diabetes mellitus (from the Bypass Angioplasty Revascularization Investigation 2 Diabetes Study). Am J Cardiol (2009) 1.42
Metallothionein prevents diabetes-induced deficits in cardiomyocytes by inhibiting reactive oxygen species production. Diabetes (2003) 1.41
Lipotoxicity in type 2 diabetic cardiomyopathy. Cardiovasc Res (2011) 1.40
The epidemiology of cardiovascular disease in type 2 diabetes mellitus: how sweet it is ... or is it? Lancet (1997) 1.40
Expression of connective tissue growth factor is increased in injured myocardium associated with protein kinase C beta2 activation and diabetes. Diabetes (2002) 1.39
Defective intracellular Ca(2+) signaling contributes to cardiomyopathy in Type 1 diabetic rats. Am J Physiol Heart Circ Physiol (2002) 1.38
Superoxide production by NAD(P)H oxidase and mitochondria is increased in genetically obese and hyperglycemic rat heart and aorta before the development of cardiac dysfunction. The role of glucose-6-phosphate dehydrogenase-derived NADPH. Am J Physiol Heart Circ Physiol (2009) 1.38
Type 1 diabetic cardiomyopathy in the Akita (Ins2WT/C96Y) mouse model is characterized by lipotoxicity and diastolic dysfunction with preserved systolic function. Am J Physiol Heart Circ Physiol (2009) 1.36
Increased myocardial fatty acid metabolism in patients with type 1 diabetes mellitus. J Am Coll Cardiol (2006) 1.35
Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated? BMJ (2007) 1.34
Long-term severe diabetes only leads to mild cardiac diastolic dysfunction in Zucker diabetic fatty rats. Eur J Heart Fail (2012) 1.33
RAGE biology, atherosclerosis and diabetes. Clin Sci (Lond) (2011) 1.32
Cell death and diabetic cardiomyopathy. Cardiovasc Toxicol (2003) 1.32
Reduced MMP-2 activity contributes to cardiac fibrosis in experimental diabetic cardiomyopathy. Basic Res Cardiol (2008) 1.30
Cardiac myocyte apoptosis is associated with increased DNA damage and decreased survival in murine models of obesity. Circ Res (2005) 1.30
Clinical impact of left ventricular hypertrophy and implications for regression. Prog Cardiovasc Dis (2009) 1.27
Effects of diet-induced obesity on inflammation and remodeling after myocardial infarction. Am J Physiol Heart Circ Physiol (2006) 1.27
Tumor necrosis factor-alpha antagonism protects from myocardial inflammation and fibrosis in experimental diabetic cardiomyopathy. Basic Res Cardiol (2007) 1.27
Determinants of hospital admission and case fatality in diabetic patients with myocardial infarction. Diabetes Care (1988) 1.25
Nutrient stress activates inflammation and reduces glucose metabolism by suppressing AMP-activated protein kinase in the heart. Diabetes (2009) 1.23
Mechanisms determining course and outcome of diabetic patients who have had acute myocardial infarction. Ann Intern Med (1997) 1.23
Screening for heart disease in diabetic subjects. Am Heart J (2005) 1.22
Diabetes mellitus worsens diastolic left ventricular dysfunction in aortic stenosis through altered myocardial structure and cardiomyocyte stiffness. Circulation (2011) 1.22
Diabetes, oxidative stress, nitric oxide and mitochondria function. Curr Diabetes Rev (2009) 1.20
Cardioprotective and anti-inflammatory effects of interleukin converting enzyme inhibition in experimental diabetic cardiomyopathy. Diabetes (2007) 1.20
Collagen remodelling in myocardia of patients with diabetes. J Clin Pathol (1993) 1.19
Myocardial insulin resistance and cardiac complications of diabetes. Curr Drug Targets Immune Endocr Metabol Disord (2005) 1.17
Increased mortality of diabetics after acute myocardial infarction attributed to diffusely impaired left ventricular performance as assessed by echocardiography. Jpn Heart J (1988) 1.16
Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care (2007) 1.16
Myocardial infarction and heart failure in the db/db diabetic mouse. Am J Physiol Heart Circ Physiol (2005) 1.14
Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. Am Heart J (2005) 1.14
Streptozotocin-induced hyperglycemia exacerbates left ventricular remodeling and failure after experimental myocardial infarction. J Am Coll Cardiol (2003) 1.13
Flow mediated dilatation and cardiac function in type 1 diabetes mellitus. Am J Cardiol (2005) 1.13
Interplay between impaired calcium regulation and insulin signaling abnormalities in diabetic cardiomyopathy. Nat Clin Pract Cardiovasc Med (2008) 1.12
Chronic inhibition of pyruvate dehydrogenase in heart triggers an adaptive metabolic response. J Biol Chem (2011) 1.11
Lipids in the heart: a source of fuel and a source of toxins. Curr Opin Lipidol (2007) 1.10
Regulators of G protein signalling: a spotlight on emerging functions in the cardiovascular system. Curr Opin Pharmacol (2007) 1.07
The incidence of congestive heart failure associated with antidiabetic therapies. Diabetes Metab Res Rev (2005) 1.04
Dyslipidaemia in type II diabetic mice does not aggravate contractile impairment but increases ventricular stiffness. Cardiovasc Res (2007) 1.04
Oxidative stress and stress signaling: menace of diabetic cardiomyopathy. Acta Pharmacol Sin (2005) 1.04
Role of differential signaling pathways and oxidative stress in diabetic cardiomyopathy. Curr Cardiol Rev (2010) 1.03
New insights into insulin resistance in the diabetic heart. Trends Endocrinol Metab (2011) 1.03
Prevalence and mortality of acute myocardial infarction in patients with diabetes. Diabetes Care (1985) 1.03
Overexpression of glutathione peroxidase attenuates myocardial remodeling and preserves diastolic function in diabetic heart. Am J Physiol Heart Circ Physiol (2006) 1.02
Left ventricular hypertrophy in hypertension: stimuli, patterns, and consequences. Hypertens Res (1999) 1.02
Obesity promotes left ventricular concentric rather than eccentric geometric remodeling and hypertrophy independent of blood pressure. Am J Hypertens (2008) 0.99
Acute myocardial infarction in diabetes mellitus and significance of congestive heart failure as a prognostic factor. Am J Cardiol (1988) 0.99
PKCβ inhibition with ruboxistaurin reduces oxidative stress and attenuates left ventricular hypertrophy and dysfunction in rats with streptozotocin-induced diabetes. Clin Sci (Lond) (2012) 0.98
Streptozotocin directly impairs cardiac contractile function in isolated ventricular myocytes via a p38 map kinase-dependent oxidative stress mechanism. Biochem Biophys Res Commun (2004) 0.98
Insulin and the heart. Diabetes Res Clin Pract (2011) 0.96
Cardiac remodeling rather than disturbed myocardial energy metabolism is associated with cardiac dysfunction in diabetic rats. Int J Cardiol (2007) 0.96
Diabetes increases apoptosis and necrosis in both ischemic and nonischemic human myocardium: role of caspases and poly-adenosine diphosphate-ribose polymerase. J Thorac Cardiovasc Surg (2007) 0.96
Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med (2012) 6.60
The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation (2006) 6.58
Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. J Am Coll Cardiol (2008) 2.89
TNF-alpha acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle. FASEB J (2005) 2.81
Mitral valve surgery in heart failure: insights from the Acorn Clinical Trial. J Thorac Cardiovasc Surg (2006) 2.62
Infectious complications in patients with left ventricular assist device: etiology and outcomes in the continuous-flow era. Ann Thorac Surg (2010) 2.23
Prediction of mode of death in heart failure: the Seattle Heart Failure Model. Circulation (2007) 2.22
Increased myocardial gene expression of tumor necrosis factor-alpha and nitric oxide synthase-2: a potential mechanism for depressed myocardial function in hibernating myocardium in humans. Circulation (2002) 2.11
Heart failure guidelines, performance measures, and the practice of medicine: mind the gap. J Am Coll Cardiol (2010) 2.06
A pivotal role for endogenous TGF-beta-activated kinase-1 in the LKB1/AMP-activated protein kinase energy-sensor pathway. Proc Natl Acad Sci U S A (2006) 2.03
The emerging role of microRNAs in cardiac remodeling and heart failure. Circ Res (2008) 1.94
Deep RNA sequencing reveals dynamic regulation of myocardial noncoding RNAs in failing human heart and remodeling with mechanical circulatory support. Circulation (2014) 1.76
TNF provokes cardiomyocyte apoptosis and cardiac remodeling through activation of multiple cell death pathways. J Clin Invest (2007) 1.75
Circulating levels of tumor necrosis factor correlate with indexes of depressed heart rate variability: a study in patients with mild-to-moderate heart failure. Chest (2003) 1.73
In search of new therapeutic targets and strategies for heart failure: recent advances in basic science. Lancet (2011) 1.69
Proapoptotic effects of caspase-1/interleukin-converting enzyme dominate in myocardial ischemia. Circ Res (2005) 1.64
Effects of phosphodiesterase type 5 inhibition on systemic and pulmonary hemodynamics and ventricular function in patients with severe symptomatic aortic stenosis. Circulation (2012) 1.56
Escherichia coli LPS-induced LV dysfunction: role of toll-like receptor-4 in the adult heart. Am J Physiol Heart Circ Physiol (2002) 1.48
Advanced heart failure and transplant cardiology: a subspecialty is born. J Am Coll Cardiol (2009) 1.48
Mitochondrial tolerance to stress impaired in failing heart. J Mol Cell Cardiol (2003) 1.45
Toll-like receptor 2 modulates left ventricular function following ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol (2006) 1.43
Clinical and Echocardiographic Factors Associated With New-Onset Atrial Fibrillation in Heart Failure - Subanalysis of the WARCEF Trial. Circ J (2016) 1.43
Extracellular matrix remodeling following myocardial injury. Ann Med (2003) 1.41
Rationale and study design of the increase of vagal tone in heart failure study: INOVATE-HF. Am Heart J (2012) 1.41
Heterogeneous effects of tissue inhibitors of matrix metalloproteinases on cardiac fibroblasts. Am J Physiol Heart Circ Physiol (2005) 1.40
Cellular remodeling in heart failure disrupts K(ATP) channel-dependent stress tolerance. EMBO J (2003) 1.40
Biomarkers of inflammation in heart failure. Heart Fail Rev (2010) 1.40
Guidelines, performance measures, and the practice of medicine: mind the gap. J Card Fail (2010) 1.37
Cardiac myocyte apoptosis provokes adverse cardiac remodeling in transgenic mice with targeted TNF overexpression. Am J Physiol Heart Circ Physiol (2004) 1.24
Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. J Am Coll Cardiol (2008) 1.23
CD14-deficient mice are protected against lipopolysaccharide-induced cardiac inflammation and left ventricular dysfunction. Circulation (2002) 1.22
Role of microRNAs in cardiac remodeling and heart failure. Cardiovasc Drugs Ther (2011) 1.21
Extracellular matrix turnover and inflammatory markers independently predict functional status and outcome in chronic heart failure. J Card Fail (2008) 1.20
Nuclear factor-kappaB protects the adult cardiac myocyte against ischemia-induced apoptosis in a murine model of acute myocardial infarction. Circulation (2003) 1.18
Adaptive and maladptive effects of SMAD3 signaling in the adult heart after hemodynamic pressure overloading. Circ Heart Fail (2009) 1.17
Angiotensin II induces tumor necrosis factor biosynthesis in the adult mammalian heart through a protein kinase C-dependent pathway. Circulation (2002) 1.17
The development of myocardial fibrosis in transgenic mice with targeted overexpression of tumor necrosis factor requires mast cell-fibroblast interactions. Circulation (2011) 1.12
Effects of changes in left ventricular contractility on indexes of contractility in mice. Am J Physiol Heart Circ Physiol (2002) 1.12
Mitral valve repair in heart failure: five-year follow-up from the mitral valve replacement stratum of the Acorn randomized trial. J Thorac Cardiovasc Surg (2011) 1.11
Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). J Card Fail (2011) 1.10
Load-dependent and -independent regulation of proinflammatory cytokine and cytokine receptor gene expression in the adult mammalian heart. Circulation (2002) 1.09
Transforming growth factor-beta receptor antagonism attenuates myocardial fibrosis in mice with cardiac-restricted overexpression of tumor necrosis factor. Basic Res Cardiol (2007) 1.08
Cross-regulation between the renin-angiotensin system and inflammatory mediators in cardiac hypertrophy and failure. Cardiovasc Res (2004) 1.07
Targeted cancer therapeutics: the heartbreak of success. Nat Med (2006) 1.06
Cyclooxygenase-2 inhibitor treatment improves left ventricular function and mortality in a murine model of doxorubicin-induced heart failure. Circulation (2004) 1.05
Negative inotropic effects of high-mobility group box 1 protein in isolated contracting cardiac myocytes. Am J Physiol Heart Circ Physiol (2008) 1.05
Inflammatory mediators and the failing heart: a translational approach. Curr Mol Med (2003) 1.04
Sustained benefits of the CorCap Cardiac Support Device on left ventricular remodeling: three year follow-up results from the Acorn clinical trial. Ann Thorac Surg (2007) 1.04
Acute decompensated heart failure: contemporary medical management. Tex Heart Inst J (2009) 1.04
Myocardial proinflammatory cytokine expression and left ventricular remodeling in patients with chronic mitral regurgitation. Circulation (2003) 1.03
Downregulation of connexin40 and increased prevalence of atrial arrhythmias in transgenic mice with cardiac-restricted overexpression of tumor necrosis factor. Am J Physiol Heart Circ Physiol (2006) 1.02
Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure. J Card Fail (2002) 1.01
Angiotensin-receptor blockade in acute myocardial infarction--a matter of dose. N Engl J Med (2003) 1.00
Innate immunity mediates myocardial preconditioning through Toll-like receptor 2 and TIRAP-dependent signaling pathways. Am J Physiol Heart Circ Physiol (2010) 0.97
Targeted overexpression of noncleavable and secreted forms of tumor necrosis factor provokes disparate cardiac phenotypes. Circulation (2003) 0.96
Desmin mediates TNF-alpha-induced aggregate formation and intercalated disk reorganization in heart failure. J Cell Biol (2008) 0.96
Activation and functional significance of the renin-angiotensin system in mice with cardiac restricted overexpression of tumor necrosis factor. Circulation (2003) 0.96
NHLBI's program for VAD therapy for moderately advanced heart failure: the REVIVE-IT pilot trial. J Card Fail (2010) 0.94
Functional significance of inflammatory mediators in a murine model of resuscitated hemorrhagic shock. Am J Physiol Heart Circ Physiol (2005) 0.93
The cytoprotective effects of tumor necrosis factor are conveyed through tumor necrosis factor receptor-associated factor 2 in the heart. Circ Heart Fail (2009) 0.93
Positioning of inflammatory biomarkers in the heart failure landscape. J Cardiovasc Transl Res (2013) 0.93
Duality of innate stress responses in cardiac injury, repair, and remodeling. J Mol Cell Cardiol (2004) 0.93
Inhibition of PPAR-alpha activity in mice with cardiac-restricted expression of tumor necrosis factor: potential role of TGF-beta/Smad3. Am J Physiol Heart Circ Physiol (2006) 0.92
Cardiac disease in cancer patients: an overview. Prog Cardiovasc Dis (2010) 0.92
The adverse impact of diabetes mellitus on left ventricular remodeling and function in patients with severe aortic stenosis. Circ Heart Fail (2011) 0.91
Review of side-effect profile of combination ezetimibe and statin therapy in randomized clinical trials. Am J Cardiol (2008) 0.90
Angiotensin II as an inflammatory mediator: evolving concepts in the role of the renin angiotensin system in the failing heart. Cardiovasc Drugs Ther (2002) 0.90
Comparison of patients with heart failure and preserved left ventricular ejection fraction among those with versus without diabetes mellitus. Am J Cardiol (2009) 0.89
Apoptosis and the heart: a decade of progress. J Mol Cell Cardiol (2004) 0.89
Benefit of warfarin compared with aspirin in patients with heart failure in sinus rhythm: a subgroup analysis of WARCEF, a randomized controlled trial. Circ Heart Fail (2013) 0.89
Therapeutic targeting of innate immunity in the failing heart. J Mol Cell Cardiol (2010) 0.89
Targeted overexpression of transmembrane tumor necrosis factor provokes a concentric cardiac hypertrophic phenotype. Circulation (2003) 0.88
Comparable performance of the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with preserved and reduced ejection fraction. Circ Heart Fail (2013) 0.87
Prognostic significance of biomarkers in predicting outcome in patients with coronary artery disease and left ventricular dysfunction: results of the biomarker substudy of the Surgical Treatment for Ischemic Heart Failure trials. Circ Heart Fail (2013) 0.87
Treatment of the metabolic syndrome: the impact of lifestyle modification. Curr Atheroscler Rep (2005) 0.87
Oxidative stress promotes ligand-independent and enhanced ligand-dependent tumor necrosis factor receptor signaling. J Biol Chem (2008) 0.86
Failure of benefit and early hazard of bucindolol for Class IV heart failure. J Card Fail (2003) 0.85
Use of biomarkers in the management of heart failure: are we there yet? Circulation (2003) 0.84
Tumor necrosis factor receptor-associated factor 2 signaling provokes adverse cardiac remodeling in the adult mammalian heart. Circ Heart Fail (2013) 0.84
Dysferlin mediates the cytoprotective effects of TRAF2 following myocardial ischemia reperfusion injury. J Am Heart Assoc (2014) 0.84
Communication in the heart: the role of the innate immune system in coordinating cellular responses to ischemic injury. J Cardiovasc Transl Res (2012) 0.84
Speckle strain echocardiography predicts outcome in patients with heart failure with both depressed and preserved left ventricular ejection fraction. Echocardiography (2014) 0.84
New predictive models of heart failure mortality using time-series measurements and ensemble models. Circ Heart Fail (2011) 0.83
Xanthine oxidase inhibition for hyperuricemic heart failure patients: design and rationale of the EXACT-HF study. Circ Heart Fail (2013) 0.83
The role of innate immune responses in the heart in health and disease. Trends Cardiovasc Med (2004) 0.83
Soluble tumor necrosis factor receptors and heart failure risk in older adults: Health, Aging, and Body Composition (Health ABC) Study. Circ Heart Fail (2013) 0.83
Epidemiology and natural history of recovery of left ventricular function in recent onset dilated cardiomyopathies. Curr Heart Fail Rep (2013) 0.82
Comparison of outcomes of white versus black patients hospitalized with heart failure and preserved ejection fraction. Am J Cardiol (2004) 0.82
Improving outcomes in heart failure: It's not unusual beyond usual care. Circulation (2002) 0.82
The vagus nerve and autonomic imbalance in heart failure: past, present, and future. Heart Fail Rev (2011) 0.82
Antiinflammatory therapy in myocarditis. Curr Opin Cardiol (2003) 0.82
Myocardial expression levels of micro-ribonucleic acids in patients with left ventricular assist devices signature of myocardial recovery, signature of reverse remodeling, or signature with no name? J Am Coll Cardiol (2011) 0.82
New insights into mechanisms of action of carvedilol treatment in chronic heart failure patients--a matter of time for contractility. J Card Fail (2011) 0.82
Widespread Down-Regulation of Cardiac Mitochondrial and Sarcomeric Genes in Patients With Sepsis. Crit Care Med (2017) 0.82
Inflammation and treatment response to sertraline in patients with coronary heart disease and comorbid major depression. J Psychosom Res (2011) 0.81
Exercise training and skeletal muscle inflammation in chronic heart failure: feeling better about fatigue. J Am Coll Cardiol (2003) 0.81
The COMET trial. Congest Heart Fail (2005) 0.81
Cardiac Risk Markers and Response to Depression Treatment in Patients With Coronary Heart Disease. Psychosom Med (2016) 0.80